AEON Biopharma, Inc. (AEON) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.92M | 5.51M | 2.49M | 4.34M | 462K | 2.32M | 4.02M | -153.47M | 74.15M | 34.73M | 15.03M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.88M | 3.89M | 1.93M | 3.26M | 3.13M | 2.63M | 3.04M | 3.32M | 4.65M | 4.68M | 5.5M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.03M | 1.61M | 597K | 1.06M | 825K | 3.04M | 972K | 4.44M | 5.73M | 6.86M | 9.53M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 10K | -37K | 16K | -1000K | -1000K | 0 | -1000K | 1000K | 1000K | 0 |
| Operating Income | -5.94M | -5.51M | -2.49M | -4.34M | -462K | -2.32M | -4.02M | 153.47M | -74.15M | -34.73M | -15.03M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -1185.06% | -137.44% | 37.92% | -102.83% | 99.38% | 93.32% | - | - | - | -131.01% | - |
| EBITDA | -5.92M | -5.49M | -2.47M | -4.32M | -443K | -2.3M | -3.99M | 153.5M | -74.13M | -34.7M | -15M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -1235.89% | -138.95% | 38.01% | -102.81% | 99.4% | 93.38% | - | - | - | -131.34% | - |
| D&A (Non-Cash Add-back) | 19K | 20K | 19K | 20K | 19K | 23K | 25K | 24K | 25K | 24K | 32K |
| EBIT | -5.94M | -5.5M | -2.53M | -4.32M | -3.95M | -5.67M | -4.02M | -7.76M | -10.38M | -11.54M | -15.03M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -5.86M | -31.63M | -2.04M | -2.3M | 9.56M | 4.4M | -2.15M | 10.64M | -43.87M | 8.48M | -19.53M |
| Pretax Income | -11.79M | -37.14M | -4.54M | -6.64M | 9.1M | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M | -34.56M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.79M | -37.14M | -4.54M | -6.64M | 9.1M | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M | -34.56M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -229.66% | -1883.72% | 26.46% | -104.05% | 107.71% | 107.93% | - | - | - | 24.07% | - |
| Net Income (Continuing) | -11.79M | -37.14M | -4.54M | -6.64M | 9.1M | 2.08M | -6.17M | 164.11M | -118.02M | -26.24M | -34.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.09M |
| EPS (Diluted) | -0.97 | -3.07 | -0.39 | -0.60 | 2.28 | 3.47 | -11.24 | 304.00 | -227.87 | -50.85 | -17.92 |
| EPS Growth % | -142.54% | -188.47% | 96.53% | -100.2% | 101% | 106.82% | - | - | - | -183.76% | - |
| EPS (Basic) | -0.97 | -3.07 | -0.39 | -0.60 | 2.28 | 3.76 | -11.53 | 304.00 | -228.27 | -50.86 | -17.93 |
| Diluted Shares Outstanding | 12.11M | 12.11M | 11.63M | 11.09M | 3.98M | 555.34K | 548.82K | 539.84K | 517.91K | 516.11K | 1.93M |
| Basic Shares Outstanding | 12.11M | 12.11M | 11.63M | 11.07M | 3.98M | 600K | 535K | 539K | 517K | 516K | 1.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |